A next-generation solid oral platform designed to overcome the fundamental limitations of conventional cannabinoid formulations—enabling predictable exposure, improved bioavailability, and clinically relevant performance.
The Challenge
Cannabinoid drug development is constrained by well-recognised challenges:
These factors collectively lead to unpredictable pharmacokinetics and inconsistent clinical outcomes.
Platform Approach
Our platform is built on a solid-state nano-enabled architecture designed to control how cannabinoids are absorbed, distributed, and sustained in the body. Without relying on conventional lipid-heavy liquid systems, the platform enables:
Controlled release profiles (immediate + sustained phases)
Reduced variability across patients
Improved systemic exposure
Independence from dietary conditions
The result is a more predictable and clinically usable cannabinoid formulation framework.
Technology
This enables transition from lab-scale formulation to scalable, GMP-compatible manufacturing pathways.
Nano-scale encapsulation within a solid-state matrix
Structured release kinetics enabling phased absorption
Excipient systems designed for stability and manufacturability
Standard oral dosage form compatibility
Performance
The platform has been evaluated through structured pharmacokinetic and clinical assessment frameworks, and is designed to bridge in vitro behaviour with in vivo outcomes, enabling predictable translation.
Enhanced Exposure
Improved systemic exposure vs conventional oral approaches
Reduced Variability
Consistent performance across dosing conditions
Controlled Release
Release behaviour aligned with therapeutic needs
Food-Independent
Consistent across fed and fasted states
Safety & Tolerability
The platform avoids many limitations associated with liquid cannabinoid formulations, supporting long-term clinical usability and patient adherence.
Stability & Manufacturability
The platform is designed with global deployment in mind, enabling scalable and commercially viable product development pathways.
Stable under standard and accelerated conditions
Suitable for high-temperature and high-humidity environments
Compatible with conventional oral solid manufacturing
Robust packaging strategies for environmental protection
Platform Flexibility
The delivery architecture is modular and can be tailored across a broad range of applications.
Strategic Value
It represents a platform approach — not a single product.
Clinical differentiation beyond existing liquid formulations
Reduced development risk through improved predictability
Regulatory alignment through structured CMC design
Lifecycle extension and new formulation opportunities
Collaboration
Our approach integrates scientific insight, formulation engineering, and regulatory and translational strategy to co-develop clinically meaningful cannabinoid therapies.
Molecules requiring improved delivery and performance
Clinical programmes needing enhanced pharmacokinetic control
New product development and lifecycle management strategies
Get in Touch
Whether you are developing a cannabinoid-based therapy or seeking to improve an existing asset, our platform provides a structured pathway toward clinically viable outcomes.
Discuss your programmeConfidential engagement. IP-protected discussions.